{"id":497116,"date":"2020-07-20T13:36:02","date_gmt":"2020-07-20T13:36:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=497116"},"modified":"2020-07-20T13:36:02","modified_gmt":"2020-07-20T13:36:02","slug":"cytokine-release-syndrome-market-size-share-trends-epidemiology-forecast-till-2030","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/cytokine-release-syndrome-market-size-share-trends-epidemiology-forecast-till-2030_497116.html","title":{"rendered":"Cytokine Release Syndrome Market, Size, Share, Trends, Epidemiology Forecast till 2030"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Cytokine Release Syndrome Market, Size, Share, Trends, Epidemiology Forecast till 2030\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" alt=\"Cytokine Release Syndrome Market, Size, Share, Trends, Epidemiology Forecast till 2030\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight&#8217;s &#8220;Cytokine Release Syndrome Market Insights, Epidemiology, and Market Forecast-2030&#8221; report delivers an in-depth understanding of the Cytokine Release Syndrome, historical and forecasted epidemiology as well as the Cytokine Release Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/div>\n<p style=\"text-align: justify;\">Cytokine Release Syndrome (CRS) is an acute systemic inflammatory syndrome characterized by fever and multiple organ dysfunction that is associated with chimeric antigen receptor (CAR)-T cell therapy, therapeutic antibodies, and haploidentical allogeneic transplantation.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Epidemiology Insights<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Total number of patients who develop CRS in the 7MM in 2017 was 31<\/li>\n<li>Total number of Hematologic patients receiving CART-therapies in the 7MM was 41&nbsp;in 2017<\/li>\n<li>Cytokine Release Syndrome cases in the United States in 2017 was 31<\/li>\n<li>The population of CRS cases among the EU5 countries in 2018:-<\/li>\n<ul>\n<li>Germany -13<\/li>\n<li>France &#8211; 11<\/li>\n<li>The United Kingdom &#8211; 11<\/li>\n<li>Spain &#8211; 6&nbsp;<\/li>\n<li>Japan had Cytokine Release Syndrome cases in 2019 &#8211; 121<\/li>\n<\/ul>\n<\/ul>\n<ul style=\"text-align: justify;\">\n<li>The patients received CAR T Cell Therapies for B-cell NHL in the United States in 2017 was 24&nbsp;<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/cytokine-release-syndrome-market\" target=\"_blank\"><strong><span data-sheets-value=\"{\" data-sheets-userformat=\"{\">Scope of Cytokine Release Syndrome market Report<\/span><\/strong><\/a><\/p>\n<ul style=\"text-align: justify;\">\n<li>The report covers the descriptive overview of Cytokine Release Syndrome, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies<\/li>\n<li>Comprehensive insight has been provided into the Cytokine Release Syndrome epidemiology and treatment in the 7MM<\/li>\n<li>Additionally, an all-inclusive account of both the current and emerging therapies for Cytokine Release Syndrome are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape<\/li>\n<li>A detailed review of Cytokine Release Syndrome market; historical and forecasted is included in the report, covering drug outreach in the 7MM<\/li>\n<li>The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Cytokine Release Syndrome market<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/cytokine-release-syndrome-market\" target=\"_blank\"><strong>Cytokine Release Syndrome Market Insight<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\">Cytokine Release Syndrome market size in the 7MM in 2017 was USD 0.16 million<\/p>\n<p style=\"text-align: justify;\"><strong>Cytokine Release Syndrome Market Drivers<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Increasing incidence of Acute cytokine release syndrome (CRS)<\/li>\n<li>Increasing R&amp;D activities<\/li>\n<li>Non-competitive landscape<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Cytokine Release Syndrome&nbsp;Market Barriers<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Lack of awareness about the disease<\/li>\n<li>Lack of disease understanding<\/li>\n<li>Misdiagnosis of CRS<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/cytokine-release-syndrome-market\" target=\"_blank\"><strong>Request for sample pages<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/uploads\/0a835cc3d160968bad002e11e55314bb.jpg\" alt=\"\" \/><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/cytokine-release-syndrome-market\" target=\"_blank\"><strong>Table of contents<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\"><span>1Key Insights<\/span><br \/><span>2 Executive Summary of Cytokine Release Syndrome<\/span><br \/><span>3 Cytokine Release Syndrome Market Overview at a Glance<\/span><br \/><span>4 Disease Background and Overview Cytokine Release Syndrome<\/span><br \/><span>5 Case Reports<\/span><br \/><span>6 Cytokine Release Syndrome Epidemiology and Patient Population<\/span><br \/><span>7 United States Epidemiology<\/span><br \/><span>8 EU5 Epidemiology<\/span><br \/><span>8.1 Assumptions and Rationale<\/span><br \/><span>8.2 Germany Epidemiology<\/span><br \/><span>8.3 France Epidemiology<\/span><br \/><span>8.4 Italy Epidemiology<\/span><br \/><span>8.5 Spain Epidemiology<\/span><br \/><span>8.6 United Kingdom Epidemiology<\/span><br \/><span>9 Japan Epidemiology<\/span><br \/><span>10 Current Cytokine Release Syndrome Treatment and Medical Practices<\/span><br \/><span>11 Unmet needs<\/span><br \/><span>12 Cytokine Release Syndrome Marketed Drugs<\/span><br \/><span>12.1 Actemra\/RoActemra (tocilizumab): Genentech<\/span><br \/><span>13 Cytokine Release Syndrome Emerging Drugs<\/span><br \/><span>13.1 Key Cross Competition<\/span><br \/><span>13.2 Canakinumab (Ilaris): Novartis Pharmaceuticals<\/span><br \/><span>13.3 Itacitinib: Incyte Corporation<\/span><br \/><span>13.4 Cytosorb: CytoSorbents<\/span><br \/><span>13.5 Defitelio (Defibrotide): Jazz pharmaceuticals<\/span><br \/><span>13.6 Anakinra: Swedish Orphan Biovitrum (Sobi)<\/span><br \/><span>14 Cytokine Release Syndrome 7MM Market Analysis<\/span><br \/><span>15 Conjoint Analysis<\/span><br \/><span>16 United States<\/span><br \/><span>16.1 United States Market Outlook<\/span><br \/><span>16.2 United States Market Size<\/span><br \/><span>17 EU-5 Countries: Market Outlook<\/span><br \/><span>17.1 Germany Market Size<\/span><br \/><span>17.2 France Market Size<\/span><br \/><span>17.3 Italy Market Size<\/span><br \/><span>17.4 Spain Market Size<\/span><br \/><span>17.5 United Kingdom Market Size<\/span><br \/><span>18 Japan Market Outlook<\/span><br \/><span>19 Cytokine Release Syndrome Market Drivers<\/span><br \/><span>20 Cytokine Release Syndrome Market Barriers<\/span><br \/><span>21 SWOT Analysis<\/span><br \/><span>22 Reimbursement and market access<\/span><br \/><span>23 Appendix<\/span><br \/><span>24 DelveInsight Capabilities<\/span><br \/><span>25 Disclaimer<\/span><br \/><span>26 About DelveInsight<\/span><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56407.html\" rel=\"nofollow\">DelveInsight<\/a><br \/><strong>Contact Person:<\/strong> DelveInsight<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=cytokine-release-syndrome-market-size-share-trends-epidemiology-forecast-till-2030\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +919650213330<br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=cytokine-release-syndrome-market-size-share-trends-epidemiology-forecast-till-2030\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight Business Research LLP DelveInsight&#8217;s &#8220;Cytokine Release Syndrome Market Insights, Epidemiology, and Market Forecast-2030&#8221; report delivers an in-depth understanding of the Cytokine Release Syndrome, historical and forecasted epidemiology as well as the Cytokine Release Syndrome market trends in the United &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/cytokine-release-syndrome-market-size-share-trends-epidemiology-forecast-till-2030_497116.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[406,423,420,403,404],"tags":[],"class_list":["post-497116","post","type-post","status-publish","format-standard","hentry","category-Pharmaceuticals-Biotech","category-Professional-Services","category-Science","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/497116","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=497116"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/497116\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=497116"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=497116"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=497116"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}